1921
Volume 97, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Antiretroviral treatment (ART) interruptions increase the risk of severe morbidity/mortality in human immunodeficiency virus (HIV)-infected individuals from subSaharan Africa. We aimed to determine whether the risk is further increased among HIV–hepatitis B virus (HBV) co-infected patients in this setting. In this sub-analysis of a randomized-control trial, 632 participants from Côte d’Ivoire randomized to receive continuous-ART (C-ART), structured ART interruptions of 2-months off, 4-months on (2/4-ART), and CD4-guided ART interruptions (CD4GT, interruption at 350/mm and reintroduction at 250/mm) were analyzed. Incidence rates (IR) of serious HIV- and non-HIV-related morbidity were compared between patients stratified on hepatitis B surface antigen (HBsAg) status. Overall, 65 (10.3%) were HBsAg-positive, 29 (44.6%) of whom had HBV-DNA levels > 10,000 copies/mL. After a median 2.0 year (range = 0.2–3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV–HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, = 0.3), whereas the highest incidence was observed in co-infected patients with baseline HBV-replication > 10,000 copies/mL (IR = 24.0/100 person/years, versus HIV mono-infected = 0.002). Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, = 0.001). The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups ( for interaction = 0.4). No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients ( = 0.5), even at HBV-replication levels > 10,000 copies/mL ( = 0.7). In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-1016
2017-10-30
2020-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/97/6/tpmd161016.html?itemId=/content/journals/10.4269/ajtmh.16-1016&mimeType=html&fmt=ahah

References

  1. Danel C et al., .; Trivacan ANRS 1269 Trial Group, 2006. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367: 19811989.
    [Google Scholar]
  2. Danel C et al., .; Trivacan ANRS 1269 Trial Group, 2009. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis 199: 6676.
    [Google Scholar]
  3. Ananworanich J et al., .; Staccato Study Group; Swiss HIV Cohort Study, 2006. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 368: 459465.
    [Google Scholar]
  4. El-Sadr WM et al., .; Strategies for Management of Antiretroviral Therapy (SMART) Study Group, 2006. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 22832296.
    [Google Scholar]
  5. Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL, 2012. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 55: 507513.
    [Google Scholar]
  6. Kouamé GM et al., 2017. Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication. Clin Infect Dis, 10.1093/cid/cix747.
    [Google Scholar]
  7. Piroth L et al., .; GERMIVIC Study Group, 2010. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 53: 10061012.
    [Google Scholar]
  8. Piroth L et al., .; GERMIVIC Study Group, 2015. Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. Liver Int 35: 19501958.
    [Google Scholar]
  9. Tedaldi E et al., .; SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), 2008. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 47: 14681475.
    [Google Scholar]
  10. Dore GJ et al., .; SMART INSIGHT Study Group, 2010. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 24: 857865.
    [Google Scholar]
  11. Matthews PC, Geretti AM, Goulder PJR, Klenerman P, 2014. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol 61: 2033.
    [Google Scholar]
  12. Hoffmann CJ, Thio CL, 2007. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7: 402409.
    [Google Scholar]
  13. Boyd A et al., .; ANRS 12240 VarBVA Study, 2015. Identifying patients infected with hepatitis B virus in Sub-Saharan Africa: potential for misclassification. Diagn Microbiol Infect Dis 83: 248251.
    [Google Scholar]
  14. Boyd A et al., .; ANRS 12240 VarBVA Study. 2015. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d’Ivoire. Antivir Ther 20: 643654.
    [Google Scholar]
  15. Rouet F et al., 2005. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 43: 27092717.
    [Google Scholar]
  16. Velen K, Charalambous S, Innes C, Churchyard GJ, Hoffmann CJ, 2016. Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study. HIV Med 17: 702707.
    [Google Scholar]
  17. Hammer SM et al., .; International AIDS Society-USA. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555570.
    [Google Scholar]
  18. Anglaret X et al., .; ANRS 12222 Morbidity/Mortality Study Group, 2012. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire. Clin Infect Dis 54: 714723.
    [Google Scholar]
  19. Nahon P et al., .; ANRS CO12 CirVir and Microcir Groups. 2017. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut 66: 330341.
    [Google Scholar]
  20. Chun HM et al., Infectious Disease Clinical Research Program HIV Working Group, 2012. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 205: 185193.
    [Google Scholar]
  21. Matthews GV et al., .; PHIDISA II Study Team, 2011 Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25: 17271735.
    [Google Scholar]
  22. Sarfo FS, Kasim A, Phillips R, Geretti AM, Chadwick DR, 2014. Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana. J Infect 69: 481489.
    [Google Scholar]
  23. Hawkins C, Christian B, Ye J, Nagu T, Aris E, Chalamilla G, Spiegelman D, Mugusi F, Mehta S, Fawzi W, 2013. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS 27: 919927.
    [Google Scholar]
  24. Chen C-J, Yang H-I, Iloeje UH; REVEAL-HBV Study Group, 2009. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49 (Suppl 5): S72S84.
    [Google Scholar]
  25. Moh R et al., 2007. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21: 24832491.
    [Google Scholar]
  26. Smith C et al., .; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, 2010. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 24: 15371548.
    [Google Scholar]
  27. Riou J, Aït Ahmed M, Blake A, Vozlinsky S, Brichler S, Eholié S, Boëlle P-Y, Fontanet A; HCV Epidemiology in Africa Group, 2016. Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat 23: 244255.
    [Google Scholar]
  28. Wandeler G et al., .; Swiss HIV Cohort Study, 2013. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis 208: 14541458.
    [Google Scholar]
  29. Matthews GV et al., 2013. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 56: e87e94.
    [Google Scholar]
  30. Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard P-M, Zoulim F, Lacombe K, 2014. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology 60: 497507.
    [Google Scholar]
  31. Boyer S, Clerc I, Bonono C-R, Marcellin F, Bilé P-C, Ventelou B, 2011. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: individual and healthcare supply-related factors. Soc Sci Med 72: 13831392.
    [Google Scholar]
  32. Auld AF et al., 2014. Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults--seven African countries, 2004–2013. MMWR Morb Mortal Wkly Rep 63: 10971103.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-1016
Loading
/content/journals/10.4269/ajtmh.16-1016
Loading

Data & Media loading...

Supplemental Table

  • Received : 23 Dec 2016
  • Accepted : 19 Aug 2017
  • Published online : 30 Oct 2017
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error